Abstract: The present invention relates to methods and systems for high risk screening, diagnosis, prognosis, and surveillance of lung cancer. Accordingly, in one aspect, the invention provides a method for diagnosing or evaluating whether a subject has, or is at risk of having, lung cancer such as NSCLS. The method comprises obtaining a first expression level of the AKAP4 gene of a population of cells from the blood of a test subject; and comparing the first expression level with a first predetermined reference value. A difference between the first expression level and first predetermined reference value correlates with a diagnosis or evaluation of a lung cancer.
Type:
Grant
Filed:
June 2, 2015
Date of Patent:
August 18, 2020
Assignees:
Valley Health System, The Wistar Institute of Anatomy and Biology
Inventors:
Kiranmai Gumireddy, Qihong Huang, Louise C. Showe, Ganepola A Ganepola
Abstract: The present invention relates to methods and systems for high risk screening, diagnosis, prognosis, and surveillance of lung cancer. Accordingly, in one aspect, the invention provides a method for diagnosing or evaluating whether a subject has, or is at risk of having, lung cancer such as NSCLS. The method comprises obtaining a first expression level of the AKAP4 gene of a population of cells from the blood of a test subject; and comparing the first expression level with a first predetermined reference value. A difference between the first expression level and first predetermined reference value correlates with a diagnosis or evaluation of a lung cancer.
Type:
Application
Filed:
June 2, 2015
Publication date:
June 13, 2019
Applicants:
Valley Health System, The Wistar Institute
Inventors:
Kiranmai Gumireddy, Qihong Huang, Louise C. Showe, Ganepola A. Ganepola